SAKK
WE BRING PROGRESS TO CANCER CARE

Quality Policy of SAKK

The Swiss Group for Clinical Cancer Research (SAKK) is committed to conducting clinical trials in oncology as a non-profit organization. It is our goal to investigate new cancer therapies and to improve existing cancer treatments, taking into account all available treatment options that help cure the disease or prolong survival and improve the quality of life of cancer patients. We conduct research through a national network and in cooperation with centers and study groups abroad.

Our main priorities for all SAKK trial processes are to ensure the rights, safety and well-being of the patients, the integrity and reliability of clinical trial data and the protection of data privacy. Therefore, we have integrated a process-oriented Quality Management System (QMS), which is continuously updated into all clinical and operational practices. Our QMS assures that all SAKK activities:

- comply with national and international applicable regulatory laws and requirements
- comply with Good Clinical Practice (ICH GCP) and the ethical principles of the Declaration of Helsinki
- use risk-based approaches to focus on relevant trial activities
- are supported by state of the art quality systems and tools
- are monitored, assessed and continuously improved

Furthermore, we implemented quality measures to maximize our research potential by:

- setting the right research priorities
- using robust research designs, conduct and analysis
- proportionating regulation and management to risks
- making all information on research methods and findings accessible
- generating complete and usable reports of research

This Quality Policy was accepted by the General Assembly of SAKK on 16.11.2022 and is effective as of that date. It shall replace all previous Quality Policies.

Basel, 17.11.2022

Prof. Dr. Miklos Pless
SAKK President

PD Dr. Sacha Rothschild
SAKK Vice-President a.i.